{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:55:10Z","timestamp":1786996510745,"version":"build-2736575974"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.schres.2023.11.010","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T07:41:38Z","timestamp":1701934898000},"page":"175-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-905X","authenticated-orcid":false,"given":"Carlos","family":"De las Cuevas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-4435","authenticated-orcid":false,"given":"Emilio J.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9696-8267","authenticated-orcid":false,"given":"Jason A.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2948-3782","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Verdoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3038-0625","authenticated-orcid":false,"given":"John","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-1224","authenticated-orcid":false,"given":"Renato","family":"de Filippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-3393","authenticated-orcid":false,"given":"Peter F.J.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-2751","authenticated-orcid":false,"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5609-7134","authenticated-orcid":false,"given":"Manuel","family":"Arrojo-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8604-9638","authenticated-orcid":false,"given":"Adrian D.","family":"Bostrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-8955","authenticated-orcid":false,"given":"Emilio","family":"Fernandez-Egea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.11.010_bb0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2125.2003.01858.x","article-title":"Identification of a novel splice-site mutation in the CYP1A2 gene","volume":"56","author":"Allorge","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00606410","article-title":"Clozapine-induced agranulocytosis: a situation report up to August 1976","volume":"11","author":"Anderman","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.rpsm.2022.06.001","article-title":"A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine-treated patients: elevations in their plasma clozapine levels","volume":"15","author":"Arrojo-Romero","year":"2022","journal-title":"Rev. Psiquiatr. Salud Ment. (Engl Ed)."},{"key":"10.1016\/j.schres.2023.11.010_bb0020","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4088\/JCP.v68n0708","article-title":"Outcome following clozapine discontinuation: a retrospective analysis","volume":"68","author":"Atkinson","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1258\/rsmmsl.44.3.217","article-title":"Life after clozapine","volume":"44","author":"Baker","year":"2004","journal-title":"Med. Sci. Law"},{"key":"10.1016\/j.schres.2023.11.010_bb0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"10.1016\/j.schres.2023.11.010_bb0040","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/archpsyc.55.11.1048","article-title":"Very high cytochrome P4501A2 activity and nonresponse to clozapine","volume":"55","author":"Bender","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2023.11.010_bb0045","first-page":"S46","article-title":"Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics","volume":"37","author":"Bender","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1994.tb04385.x","article-title":"Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test","volume":"38","author":"Bertilsson","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.schres.2023.05.009","article-title":"A national pharmacovigilance study of haematological adverse drug reactions to clozapine vs other second-generation antipsychotics in Italy","volume":"257","author":"Bertoli","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0028-1094343","article-title":"Temperaturanstiege und Bluteiwei\u03b2ver\u00e4nderungen unter der Therapie mit Neuroleptika-unter besonderer Ber\u00fccksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin","volume":"5","author":"Blum","year":"1972","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JCP.0000000000001657","article-title":"Feasibility and effect of increasing clozapine plasma levels in long-stay patients with treatment-tesistant schizophrenia","volume":"43","author":"Bogers","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0070","article-title":"A 12-month audit of clozapine associated myocarditis in a South Australian local health network: the importance of screening and personalised titration","volume":"2023","author":"Carswell","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0075","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/JCP.0b013e3181b2fced","article-title":"Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics?","volume":"29","author":"Castberg","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5455\/bcp.20141223052008","article-title":"Clozaphobia; fear of prescribers of clozapine for treatment of schizophrenia","volume":"24","author":"Cetin","year":"2014","journal-title":"Bull. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/psb.405","article-title":"The Yellow Card scheme - why are GPs under-reporting?","volume":"17","author":"Chaplin","year":"2006","journal-title":"Prescriber"},{"key":"10.1016\/j.schres.2023.11.010_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.07.014","article-title":"Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: a nationwide cohort study in Taiwan","author":"Chen","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0095","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/acps.12989","article-title":"Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study","volume":"139","author":"Cho","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2019.1577134","article-title":"A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults","volume":"12","author":"Cicala","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: a systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0110","series-title":"Current Problems in Pharmacovigilance","first-page":"9","article-title":"Myocarditis with antipsychotics: recent cases with clozapine (Clozaril)","volume":"19","author":"Committee on Safety of Medicines","year":"1993"},{"key":"10.1016\/j.schres.2023.11.010_bb0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0120","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.322.7296.1207","article-title":"Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study","volume":"322","author":"Coulter","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2023.11.010_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/17512433.2020.1787831","article-title":"Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review","volume":"13","author":"de Filippis","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0135","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/02698811211021587","article-title":"Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: a systematic review","volume":"35","author":"de Filippis","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.euroneuro.2022.04.009","article-title":"Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases","volume":"60","author":"de Filippis","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.10.027","article-title":"Clozapine-associated pericarditis and pancreatitis in children and adolescents: a systematic literature review and pharmacovigilance study using VigiBase database","author":"de Filippis","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0150","first-page":"388","article-title":"Poor adherence to oral psychiatric medication in adults with schizophrenia may be influenced by pharmacophobia, high internal health locus of control and treatment duration","volume":"23","author":"De Las Cuevas","year":"2021","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.schres.2023.11.010_bb0155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.rpsm.2021.07.004","article-title":"Clozapine-associated myocarditis in the World Health Organization\u2019s pharmacovigilance database: focus on reports from various countries","volume":"15","author":"De Las Cuevas","year":"2022","journal-title":"Rev. Psiquiatr. Salud Ment. (Engl Ed)."},{"key":"10.1016\/j.schres.2023.11.010_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17512433.2022.2032659","article-title":"Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase","volume":"15","author":"De Las Cuevas","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0165","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/17425255.2022.2160318","article-title":"Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review","volume":"18","author":"De Las Cuevas","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.schres.2023.11.010_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/17425255.2023.2192401","article-title":"Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase","volume":"19","author":"De Las Cuevas","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.schres.2023.11.010_bb0175","article-title":"Adverse drug reactions and their fatal outcomes in clozapine-treated patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia)","author":"De las Cuevas","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0180","doi-asserted-by":"crossref","first-page":"411","DOI":"10.24869\/psyd.2022.411","article-title":"Reflections on the complex history of the concept of clozapine-induced inflammation during titration","volume":"34","author":"de Leon","year":"2022","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2023.11.010_bb0185","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1111\/bcp.15522","article-title":"According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world","volume":"88","author":"de Leon","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.30773\/pi.2022.0293","article-title":"Reflections on the lack of consideration of ethnic ancestry to stratify clozapine dosing","volume":"20","author":"de Leon","year":"2023","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.schres.2023.11.010_bb0195","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0278-5846(03)00148-9","article-title":"Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report","volume":"27","author":"de Leon","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0205","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.schres.2023.11.010_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/schbul\/sbz093","article-title":"Data from the World Health Organization\u2019s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions","volume":"46","author":"de Leon","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/IJPSYM.IJPSYM_379_19","article-title":"Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview","volume":"42","author":"de Leon","year":"2020","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.schres.2023.11.010_bb0215","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00406-022-01407-7","article-title":"An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s","volume":"272","author":"de Leon","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2023.11.010_bb0220","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2215-0366(22)00154-7","article-title":"Clozapine and the risk of haematological malignancies","volume":"9","author":"de Leon","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JCP.0000000000001678","article-title":"Escaping the long shadow of agranulocytosis. Reflections on a clozapine pharmacovigilance focused on the United Kingdom","volume":"43","author":"de Leon","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0235","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0447.1990.tb05295.x","article-title":"The neuroleptics: a historical survey","volume":"358","author":"Deniker","year":"1990","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2023.11.010_bb0240","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(00)00035-0","article-title":"Clozapine and sudden death","volume":"355","author":"Devarajan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.11.010_bb0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0034-1371866","article-title":"Can valproic acid be an inducer of clozapine metabolism?","volume":"47","author":"Diaz","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0250","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/15622975.2018.1500030","article-title":"Seizure rates under treatment with antipsychotic drugs: data from the AMSP project","volume":"20","author":"Druschky","year":"2019","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0255","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0029-1239542","article-title":"Clozapine intoxication in a patient with lamotrigine-induced rash","volume":"43","author":"Egger","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0260","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.rpsm.2021.10.003","article-title":"Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: a re-analysis of a Turkish case series","volume":"15","author":"Ertu\u011frul","year":"2022","journal-title":"Rev. Psiquiatr. Salud Ment. (Engl Ed)."},{"key":"10.1016\/j.schres.2023.11.010_bb0265","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/00007691-199812000-00008","article-title":"Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia","volume":"20","author":"Facciol\u00e0","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.11.010_bb0270","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-199906000-00017","article-title":"Metabolites in patients with schizophrenic or affective disorders","volume":"21","author":"Facciol\u00e0","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.11.010_bb0275","first-page":"8","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"Br. J. Psych. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0280","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ijnp\/pyz046","article-title":"Cardiovascular adverse reactions during antipsychotic treatment: results of AMSP, a drug surveillance program between 1993 and 2013","volume":"23","author":"Friedrich","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl","key":"10.1016\/j.schres.2023.11.010_bb0285","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1007\/BF00442570","article-title":"Side effects of clozapine","volume":"99","author":"Gaertner","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.11.010_bb0290","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/0269881118760666","article-title":"Long-term follow-up of clozapine prescribing","volume":"32","author":"Gee","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0295","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.4088\/JCP.16m11164","article-title":"Dried blood spot analysis for therapeutic drug monitoring of clozapine","volume":"78","author":"Geers","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0300","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00228-010-0839-9","article-title":"Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up","volume":"66","author":"Gjerden","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0305","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijbiomac.2020.03.119","article-title":"Atypical antipsychotic clozapine binds fibrinogen and affects fibrin formation","volume":"154","author":"Gligorijevi\u0107","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.schres.2023.11.010_bb0310","article-title":"Patient and caregivers perspective about clozapine: a systematic review","author":"Grover","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0315","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"Haack","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0320","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4088\/JCP.v59n0604","article-title":"Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications","volume":"59","author":"H\u00e4gg","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0325","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(00)02066-3","article-title":"Association of venous thromboembolism and clozapine","volume":"355","author":"H\u00e4gg","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.11.010_bb0330","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1192\/bjp.2022.24","article-title":"Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992-2017","volume":"220","author":"Handley","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0335","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/schbul\/sbu120","article-title":"The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders","volume":"41","author":"Hayes","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0340","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"issue":"Suppl","key":"10.1016\/j.schres.2023.11.010_bb0345","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1007\/BF00442566","article-title":"Clinical experience with clozapine in Germany","volume":"99","author":"Helmchen","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.11.010_bb0350","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0447.1995.tb09762.x","article-title":"Mortality among patients in psychiatric hospitals in Germany","volume":"91","author":"Hewer","year":"1995","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0355","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"1\u221202","key":"10.1016\/j.schres.2023.11.010_bb0360","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"5 Pt 1","key":"10.1016\/j.schres.2023.11.010_bb0365","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0013-7006(06)76220-0","article-title":"Etude r\u00e9trospective sur l'utilisation de la clozapine en Ile-de-France [Retrospective study of clozapine use in Ile-de-France]","volume":"32","author":"Hiltgen","year":"2006","journal-title":"Encephale"},{"issue":"Suppl","key":"10.1016\/j.schres.2023.11.010_bb0370","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF00442551","article-title":"The history of clozapine","volume":"99","author":"Hippius","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.11.010_bb0375","series-title":"CLOZARIL-Clozapine Tablet","author":"HLS Therapeutics, Inc","year":"2023"},{"key":"10.1016\/j.schres.2023.11.010_bb0380","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.11.010_bb0385","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","article-title":"Letter: clozapine and agranulocytosis","volume":"2","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.11.010_bb0390","series-title":"Epidemiological Issues in Reported Drug Induced Illnesses","first-page":"17","article-title":"Assessment drug safety problems","author":"Inman","year":"1976"},{"key":"10.1016\/j.schres.2023.11.010_bb0395","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.11.010_bb0400","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0447.1985.tb01268.x","article-title":"Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years","volume":"71","author":"Juul Povlsen","year":"1985","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0405","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.09.029","article-title":"Association between initial pattern of clozapine titration, concentration-to- dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital","author":"Kang","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.09.029","article-title":"Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital","author":"Kang","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0420","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4088\/JCP.08m04718yel","article-title":"Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study","volume":"71","author":"Kelly","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.06.003","article-title":"Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: a retrospective chart review of seven hospitals","author":"Kikuchi","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0430","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.11.010_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.09.020","article-title":"A scoping review of literature on clozapine from former Soviet Union states published in Russian language","author":"Kirilochev","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0440","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2013.07.043","article-title":"Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up","volume":"150","author":"Kiviniemi","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0445","first-page":"29","article-title":"Four cases of myocarditis in US hospitals possibly associated with clozapine poor metabolism and a comparison with prior published cases","volume":"24","author":"Koenig","year":"2022","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.schres.2023.11.010_bb0450","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM200107193450317","article-title":"Myocarditis and cardiomyopathy associated with clozapine use in the United States","volume":"345","author":"La Grenade","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2023.11.010_bb0455","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4088\/JCP.11m07244","article-title":"Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted","volume":"73","author":"Lahdelma","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0460","first-page":"233","article-title":"Blood dyscrasias in clozapine-treated patients in Italy","volume":"85","author":"Lambertenghi Deliliers","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.schres.2023.11.010_bb0465","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0470","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","article-title":"Reasons for discontinuing clozapine: a cohort study of patients commencing treatment","volume":"174","author":"Legge","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0475","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/WNF.0000000000000080","article-title":"Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish pharmacovigilance database","volume":"38","author":"Lertxundi","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0480","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0485","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2887","article-title":"A systematic review of clozapine-associated inflammation and related monitoring","author":"Leung","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.schres.2023.11.010_bb0490","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0013-7006(04)95441-3","article-title":"Dix ans d\u2019exp\u00e9rience clinique de la clozapine portant sur 170 patients [Ten years of clinical experience with clozapine about 170 patients]","volume":"30","author":"Levoyer","year":"2004","journal-title":"Encephale"},{"key":"10.1016\/j.schres.2023.11.010_bb0495","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/schbul\/sbac014","article-title":"Primary nonadherence to antipsychotic treatment among persons with schizophrenia","volume":"48","author":"Lieslehto","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0500","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.11.010_bb0505","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/02698811211058973","article-title":"Incident infection during the first year of treatment - a comparison of clozapine and paliperidone palmitate long-acting injection","volume":"36","author":"Mace","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0510","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1017\/S0790966700007904","article-title":"Predictors of discontinuation on clozapine: a population study","volume":"20","author":"MacGillivray","year":"2003","journal-title":"Ir. J. Psychol. Med."},{"key":"10.1016\/j.schres.2023.11.010_bb0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1819.2007.01773.x","article-title":"Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients","volume":"62","author":"Mal\u00fd","year":"2008","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2023.11.010_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103105","article-title":"Fatal pulmonary embolism in patients on antipsychotics: case series, systematic review and meta-analysis","volume":"73","author":"Manoubi","year":"2022","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.schres.2023.11.010_bb0525","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0530","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.17l02151","article-title":"Unexpected falls during clozapine treatment explained by myoclonus","volume":"20","author":"McCollum","year":"2018","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.schres.2023.11.010_bb0535","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/11536510-000000000-00000","article-title":"Yellow Card Collaboration. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals","volume":"33","author":"McLernon","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.11.010_bb0540","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.wnf.0000240955.49315.65","article-title":"Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders","volume":"30","author":"Migliardi","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0545","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0002-8703(88)90877-0","article-title":"Myocarditis presenting as acute myocardial infarction","volume":"115","author":"Miklozek","year":"1988","journal-title":"Am. Heart J."},{"key":"10.1016\/j.schres.2023.11.010_bb0550","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1111\/bcp.14851","article-title":"Fatal adverse drug reactions: a worldwide perspective in the World Health Organization pharmacovigilance database","volume":"87","author":"Montastruc","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0555","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1023\/B:PHAR.0000026808.97403.05","article-title":"Retrospective evaluation of the effect of omeprazole on clozapine metabolism","volume":"26","author":"Mookhoek","year":"2004","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.schres.2023.11.010_bb0560","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998-2005","volume":"167","author":"Moore","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.schres.2023.11.010_bb0565","first-page":"11","article-title":"\u201cSchizophrenia past clozapine\u201d: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing","volume":"48","author":"Mustafa","year":"2015","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl","key":"10.1016\/j.schres.2023.11.010_bb0570","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1007\/BF00442564","article-title":"Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia\u2014a retrospective study of 387 patients","volume":"99","author":"Naber","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.11.010_bb0580","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/sbq137","article-title":"Risk factors for ileus in patients with schizophrenia","volume":"38","author":"Nielsen","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0585","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euroneuro.2009.03.002","article-title":"Increased use of antibiotics in patients treated with clozapine","volume":"19","author":"Nielsen","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0590","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2023.11.010_bb0595","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e318267b3cd","article-title":"Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish register study","volume":"32","author":"Nielsen","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0600","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bdi.12018","article-title":"Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study","volume":"14","author":"Nielsen","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2023.11.010_bb0605","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","article-title":"Geographical and temporal variations in clozapine prescription for schizophrenia","volume":"22","author":"Nielsen","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0610","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.44.12.2247","article-title":"Clozapine-related seizures: experience with 5,629 patients","volume":"44","author":"Pacia","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.schres.2023.11.010_bb0615","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13066","article-title":"Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies","volume":"140","author":"Papola","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0620","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/pds.1801","article-title":"Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database","volume":"18","author":"Peyri\u00e8re","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.schres.2023.11.010_bb0625","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.genhosppsych.2019.07.011","article-title":"A comprehensive analysis of attempted and fatal suicide cases involving frequently used psychotropic medications","volume":"63","author":"Pfeifer","year":"2020","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0630","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e3181acd20b","article-title":"Toxic clozapine serum levels during inflammatory reactions","volume":"29","author":"Pfuhlmann","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0635","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00213-016-4411-x","article-title":"Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports","volume":"233","author":"Polcwiartek","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.11.010_bb0640","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.rpsm.2011.11.003","volume":"5","author":"Pons","year":"2012","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"10.1016\/j.schres.2023.11.010_bb0645","first-page":"1","article-title":"Clozapine is associated with secondary antibody deficiency","volume":"214","author":"Ponsford","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0650","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/20009666.2019.1627848","article-title":"Clozapine associated pulmonary embolism: systematic review","volume":"9","author":"Poudyal","year":"2019","journal-title":"J. Commun. Hosp. Intern. Med. Perspect."},{"key":"10.1016\/j.schres.2023.11.010_bb0655","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00228-002-0486-x","article-title":"Bacterial pneumonia can increase serum concentration of clozapine","volume":"58","author":"Raaska","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0660","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/pgmj.2004.031161","article-title":"Clozapine, agranulocytosis, and benign ethnic neutropenia","volume":"81","author":"Rajagopal","year":"2005","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.schres.2023.11.010_bb0665","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","author":"Reeves","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0670","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/pds.3567","article-title":"Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study","volume":"23","author":"Ringb\u00e4ck Weitoft","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.schres.2023.11.010_bb0675","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/acps.12827","article-title":"Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study","volume":"137","author":"Rohde","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0680","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1521\/pedi_2017_31_328","article-title":"Real-world effectiveness of clozapine for borderline personality disorder: results rrom a 2-year mirror-image study","volume":"32","author":"Rohde","year":"2018","journal-title":"J. Personal. Disord."},{"key":"10.1016\/j.schres.2023.11.010_bb0685","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1177\/0269881118783322","article-title":"Real-world effectiveness of clozapine for intellectual disability: results from a mirror-image and a reverse-mirror-image study","volume":"32","author":"Rohde","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0690","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/acps.13142","article-title":"Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study","volume":"142","author":"Rohde","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0695","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.euroneuro.2020.05.011","article-title":"Causes of death in clozapine-treated patients in a catchment area: a 10-year retrospective case-control study","volume":"36","author":"Rose","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0700","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2019.12.118","article-title":"Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials","volume":"32","author":"Rotella","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0705","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881120913152","article-title":"Clozapine use - has practice changed?","volume":"34","author":"Rowntree","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0710","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/0091217417749799","article-title":"Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients","volume":"53","author":"Ruan","year":"2018","journal-title":"Int. J. Psychiatry Med."},{"key":"10.1016\/j.schres.2023.11.010_bb0715","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000506355","article-title":"Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing Hospital in-patients with more than 24,000 days of clozapine treatment","volume":"89","author":"Ruan","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.schres.2023.11.010_bb0720","article-title":"Exploring low clozapine C\/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine-treated patients. A literature review and a case series of 15 patients from 3 studies","author":"Ruan","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0725","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/schbul\/17.2.247","article-title":"Update on the clinical efficacy and side effects of clozapine","volume":"17","author":"Safferman","year":"1991","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.09.002","article-title":"An expert review of clozapine in Eastern European countries: use, regulations and pharmacovigilance","author":"Sagud","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0735","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/a-0586-8983","article-title":"Clozapine-induced DRESS syndrome: a case series from the AMSP multicenter drug safety surveillance project","volume":"52","author":"Sanader","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0740","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/healthcare10061015","article-title":"Under-reporting of adverse drug reactions in Finland and healthcare professionals' perspectives on how to improve reporting","volume":"10","author":"Sandberg","year":"2020","journal-title":"Healthcare (Basel)."},{"key":"10.1016\/j.schres.2023.11.010_bb0745","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/JCP.0b013e3181ee2afe","article-title":"Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders","volume":"30","author":"Santoro","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0750","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.euroneuro.2016.07.006","article-title":"Comparative risk of death in older adults treated with antipsychotics: a population-based cohort study","volume":"26","author":"Schmedt","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0755","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JCP.0000000000000124","article-title":"Pulmonary embolism and aspiration pneumonia after reexposure to clozapine: pulmonary adverse effects of clozapine","volume":"34","author":"Schmidinger","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0760","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-2007-1017445","article-title":"Drug prescribing pattern of a psychiatric university hospital in Germany","volume":"16","author":"Schmidt","year":"1983","journal-title":"Pharmacopsychiatria"},{"key":"10.1016\/j.schres.2023.11.010_bb0765","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0770","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40262-020-00944-5","article-title":"Elevated clozapine concentrations in clozapine-treated patients with hypersalivation","volume":"60","author":"Schoretsanitis","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2023.11.010_bb0775","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17512433.2021.1877135","article-title":"An update on the complex relationship between clozapine and pneumonia","volume":"14","author":"Schoretsanitis","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0780","first-page":"153","article-title":"Should we routinely add CRP to clozapine titrations? - learning from three cases","volume":"24","author":"Shelton","year":"2022","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.schres.2023.11.010_bb0785","series-title":"The Psychopharmacologists III: Interviews by David Healy","first-page":"523","article-title":"Chapter 25","author":"Simon","year":"2000"},{"key":"10.1016\/j.schres.2023.11.010_bb0790","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0795","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.schres.2023.11.010_bb0800","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.4088\/JCP.14m08996","article-title":"Incident users of antipsychotic agents and future use of cholesterol-lowering drugs: an observational, pharmacoepidemiologic study","volume":"76","author":"Skrede","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0805","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.schres.2020.11.025","article-title":"Rates of complete nonadherence among atypical antipsychotic drugs: a study using blood samples from 13,217 outpatients with psychotic disorders","volume":"228","author":"Smith","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0810","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.euroneuro.2015.04.027","article-title":"Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study","volume":"25","author":"Sneider","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0815","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/schbul\/sbab087","article-title":"Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study","volume":"48","author":"Solmi","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0820","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-199805000-00009","article-title":"Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia","volume":"13","author":"Spina","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0825","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-2000-8361","article-title":"Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline","volume":"33","author":"Spina","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0830","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00007691-200112000-00014","article-title":"No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites","volume":"23","author":"Spina","year":"2001","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.11.010_bb0835","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.ftd.0000246763.59506.b0","article-title":"Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder","volume":"28","author":"Spina","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.11.010_bb0840","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11126-018-9621-4","article-title":"Effects of cigarette smoking and clozapine treatment on 20-year all-cause & cardiovascular mortality in schizophrenia","volume":"90","author":"Stolz","year":"2019","journal-title":"Psychiatry Q."},{"key":"10.1016\/j.schres.2023.11.010_bb0845","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia","volume":"197","author":"Taipale","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0850","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0855","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/acps.13208","article-title":"Adherence to clozapine vs. other antipsychotics in schizophrenia","volume":"142","author":"Takeuchi","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0860","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1192\/bjp.bp.108.051979","article-title":"Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection","volume":"194","author":"Taylor","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0865","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2023.11.010_bb0870","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.schres.2023.11.010_bb0875","author":"UK Medicines and Healthcare Products Regulatory Agency"},{"key":"10.1016\/j.schres.2023.11.010_bb0880","author":"UK Medicines and Healthcare Products Regulatory Agency"},{"key":"10.1016\/j.schres.2023.11.010_bb0885","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00228-002-0441-x","article-title":"Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment","volume":"58","author":"van de Vijver","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0890","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.schres.2018.08.017","article-title":"Concerns about bias in studies on clozapine and mortality","volume":"204","author":"van der Zalm","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0895","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/YIC.0000000000000292","article-title":"Use of cardiovascular and antidiabetic drugs before and after starting with clozapine versus other antipsychotic drugs: a Dutch database study","volume":"35","author":"van der Zalm","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0900","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/acps.13267","article-title":"Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study","volume":"143","author":"van der Zalm","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0905","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1590\/S0080-623420140000400023","article-title":"Causes for the underreporting of adverse drug events by health professionals: a systematic review","volume":"48","author":"Varallo","year":"2014","journal-title":"Rev. Esc. Enferm. USP."},{"key":"10.1016\/j.schres.2023.11.010_bb0910","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/a-1562-2521","article-title":"COVID-19: risks, complications, and monitoring in patients on clozapine","volume":"55","author":"Veerman","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0915","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/acps.12344","article-title":"Clozapine use pattern in persons with and without treatment for Parkinson\u2019s disease in real-world conditions: a naturalistic study in a community-based sample","volume":"130","author":"Verdoux","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0920","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/acps.13172","article-title":"Educational needs and psychoeducation interventions in clozapine users: a narrative review","volume":"142","author":"Verdoux","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0925","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/acps.12554","article-title":"Geographical disparities in prescription practices of lithium and clozapine: a community-based study","volume":"133","author":"Verdoux","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0930","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2018.05.046","article-title":"Prescriber and institutional barriers and facilitators of clozapine use: a systematic review","volume":"201","author":"Verdoux","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0935","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2019.07.040","article-title":"Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review","volume":"211","author":"Verdoux","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0940","article-title":"Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations","author":"Verdoux","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0945","article-title":"Optimizing antidepressant and clozapine co-prescription in clinical practice: a systematic review and expert recommendations","author":"Verdoux","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0950","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.11.010_bb0955","first-page":"170","article-title":"Pludselig d\u00f8d under behandling med klozapin (Leponex) [sudden death during treatment with clozapine (Leponex)]","volume":"142","author":"Vesterby","year":"1980","journal-title":"Ugeskr. Laeger"},{"key":"10.1016\/j.schres.2023.11.010_bb0960","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/acps.13184","article-title":"Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia","volume":"142","author":"Villasante-Tezanos","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0965","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40264-019-00861-y","article-title":"Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO global database of individual case safety reports","volume":"42","author":"Wakao","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2023.11.010_bb0970","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/acps.13280","article-title":"An evaluation of the variation and underuse of clozapine in the United Kingdom","volume":"143","author":"Whiskey","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.11.010_bb0975","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","article-title":"Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia","volume":"174","author":"Wimberley","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.11.010_bb0980","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/0269881110379288","article-title":"The incidence and associated risk factors for sudden unexplained death in psychiatric in-patients in England and Wales","volume":"25","author":"Windfuhr","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.11.010_bb0985","article-title":"Schizophrenia plays a negative role in the pathological development of myocardial infarction at multiple biological levels","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.schres.2023.11.010_bb0990","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1043-6618(03)00178-6","article-title":"Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia","volume":"48","author":"Zoccali","year":"2003","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.schres.2023.11.010_bb0995","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-200205000-00008","article-title":"Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine","volume":"17","author":"Zullino","year":"2002","journal-title":"Int. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642300422X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642300422X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:31:00Z","timestamp":1730799060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099642300422X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":198,"alternative-id":["S092099642300422X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.11.010","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}